Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
Year: 2017
Type: article
Abstract: Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein we characterise novel targets of doxycycline describing the structural background supporting its effectiveness as a neuroprotector at subantibiotic doses. Our results show that doxycycline reshapes α-synuclein oligomers into off-pathway, high-molecular-weight species that do not evolve into fibrils. Off-pathway species present less hydrophobic surface than on-pathway oligomers and display different β-sheet structural arrangement. These structural changes affect the α-synuclein ability to destabilize biological membranes, cell viability, and formation of additional toxic species. Altogether, these mechanisms could act synergically giving novel targets for repurposing this drug.
Source: Scientific Reports
DOI: 10.1038/srep41755
Institutions: National University of Tucumán, Centre National de la Recherche Scientifique, Consejo Nacional de Investigaciones Científicas y Técnicas, Inserm, Sorbonne Université, Institut des Sciences Moléculaires, Instituto Superior de Investigaciones Biológicas, Institut du Cerveau, Université Pierre-et-Marie-Curie, Universidade de São Paulo, National University of Rosario, Université Paris-Est Créteil, Laboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération Tissulaires
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Awards: G3572101131, G6385421210
OpenAlex ID: W2584036292
